SOUDERTON, Pennsylvania, February 14, 2011 /PRNewswire/ -- The Almac Group announced today that Graham Nicholls, Director of Biostatistics for Almac's Clinical Technologies business unit, will be speaking at the Clinical Trial Supply Europe conference (CTS Europe) held in Barcelona, Spain, 22-23 February 2011. The conference will be attended by two of Almac's business units directly involved with providing an integrated clinical supply chain solution involving IXRS(R) technology, planning, forecasting, packaging, labeling, analytical testing, inventory management, and global distribution of supplies for clinical trials.
Graham Nicholls plans to speak on the topic of the challenges of conducting adaptive trials. A notable expert on this subject, Mr. Nicholls will provide an overview of adaptive trial designs and comment on some of the current regulatory and logistical perspectives of implementing such trials on a global basis. Additionally, Mr. Nicholls will address some of the particular challenges that adaptive trial designs have on clinical supplies planning, as well as on manufacturing, packaging, and IXRS(R) technology considerations.
Jim Murphy, President of Almac's Clinical Technologies Business unit comments on the unique full service clinical supply solution offered by Almac: "Graham's knowledge of dynamic randomization strategies has helped Almac solidify its reputation as an industry leader in adaptive and other complex trial designs. Graham's knowledge complements Almac's logistical expertise in managing clinical supply chains on a global basis, providing our clients with a full-service drug supply management solution for adaptive trials that is unmatched in our industry. As we are seeing an increasing number of adaptive trials, it is important to share Graham's extensive knowledge at conferences, such as CTS Europe, to help sponsors plan and execute on complex study designs."
Almac will be showcasing its integrated technology and clinical supply chain solution at booth #19 at the CTS Europe show.
About Almac Group
The Almac Group provides a broad range of services from R&D, biomarker discovery and development, API manufacture, formulation development, clinical trial supply and IXRS technology (IVRS/IWRS), to commercial-scale manufacture. Almac provides services to more than 600 companies, including all the world leaders in the pharmaceutical and biotech sectors.
The company employs over 3,000 individuals and is headquartered in Craigavon, Northern Ireland. US operations are based in Pennsylvania, North Carolina and California. Almac has now moved into its new $120m North American Headquarters located in Souderton PA.
Almac's Clinical Technologies business unit specializes in interactive technology and service solutions to increase the quality and efficiency of clinical trials. Our solutions include Interactive Voice and Web Response Systems (IXRS(R)) for patient randomization and drug assignment, patient and clinical supplies management, electronic-patient-reported-outcomes data collection, and Web drug reconciliation. Almac's technologies have been deployed in over 1600 clinical trials, incorporating over 1.5 million patients in over 80 countries, and more than 60 languages.
For more information about the Almac Group, please visit http://www.almacgroup.com
SOURCE Almac Group